GC Cell (A144510) Stock Overview
Develops cell therapy products. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
A144510 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
GC Cell Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩26,400.00 |
| 52 Week High | ₩26,950.00 |
| 52 Week Low | ₩16,940.00 |
| Beta | 1.29 |
| 1 Month Change | 15.03% |
| 3 Month Change | 40.05% |
| 1 Year Change | 8.87% |
| 3 Year Change | -48.24% |
| 5 Year Change | -69.19% |
| Change since IPO | -45.11% |
Recent News & Updates
GC Cell Corporation (KOSDAQ:144510) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Nov 05
GC Cell (KOSDAQ:144510) Is Making Moderate Use Of Debt
Oct 31Benign Growth For GC Cell Corporation (KOSDAQ:144510) Underpins Stock's 26% Plummet
Apr 09Recent updates
GC Cell Corporation (KOSDAQ:144510) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Nov 05GC Cell (KOSDAQ:144510) Is Making Moderate Use Of Debt
Oct 31Benign Growth For GC Cell Corporation (KOSDAQ:144510) Underpins Stock's 26% Plummet
Apr 09The Market Doesn't Like What It Sees From GC Cell Corporation's (KOSDAQ:144510) Revenues Yet As Shares Tumble 27%
Dec 01Revenues Working Against GC Cell Corporation's (KOSDAQ:144510) Share Price
Oct 14Is GC Cell (KOSDAQ:144510) A Risky Investment?
Sep 08We Think Green Cross Lab Cell's (KOSDAQ:144510) Robust Earnings Are Conservative
Mar 19We Think Green Cross Lab Cell (KOSDAQ:144510) Can Stay On Top Of Its Debt
Feb 22Can Green Cross Lab Cell Corporation (KOSDAQ:144510) Improve Its Returns?
Jan 18
Can You Imagine How Jubilant Green Cross Lab Cell's (KOSDAQ:144510) Shareholders Feel About Its 139% Share Price Gain?
Dec 14Shareholder Returns
| A144510 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 6.2% | 2.6% | 2.4% |
| 1Y | 8.9% | 54.6% | 57.3% |
Return vs Industry: A144510 underperformed the KR Biotechs industry which returned 54.6% over the past year.
Return vs Market: A144510 underperformed the KR Market which returned 57.3% over the past year.
Price Volatility
| A144510 volatility | |
|---|---|
| A144510 Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in KR Market | 11.2% |
| 10% least volatile stocks in KR Market | 2.6% |
Stable Share Price: A144510's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A144510's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 752 | Jai-Wang Kim | www.gccell.com |
GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC.
GC Cell Corporation Fundamentals Summary
| A144510 fundamental statistics | |
|---|---|
| Market cap | ₩395.21b |
| Earnings (TTM) | -₩98.19b |
| Revenue (TTM) | ₩170.13b |
Is A144510 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A144510 income statement (TTM) | |
|---|---|
| Revenue | ₩170.13b |
| Cost of Revenue | ₩141.41b |
| Gross Profit | ₩28.73b |
| Other Expenses | ₩126.92b |
| Earnings | -₩98.19b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.53k |
| Gross Margin | 16.88% |
| Net Profit Margin | -57.72% |
| Debt/Equity Ratio | 16.2% |
How did A144510 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/01 08:28 |
| End of Day Share Price | 2025/12/01 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GC Cell Corporation is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jinhee Kwak | Eugene Investment & Securities Co Ltd. |
| Seung-Ho Lee | NH Investment & Securities Co., Ltd. |